Experimental HIV Drugs
Experimental HIV Drugs
AIDS 2012: Quad Matches Atripla and Atazanavir Regardless of Viral Load or CD4 Count
- Details
- Category: HIV Treatment
- Published on Friday, 17 August 2012 00:00
- Written by Liz Highleyman
The 4-in-1 Quad pill containing the next-generation integrase inhibitor elvitegravir worked as well as both the Atripla coformulation and the boosted protease inhibitor atazanavir (Reyataz) for people with either high or low baseline viral load and CD4 T-cell counts, according to 2 poster presentations at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC.
AIDS 2012: Long-acting HIV Integrase Inhibitor S/GSK1265744 May Allow Monthly Dosing
- Details
- Category: HIV Treatment
- Published on Tuesday, 07 August 2012 00:00
- Written by Liz Highleyman
A nano-suspension formulation of the next-generation integrase inhibitor S/GSK1265744 demonstrated a half-life 21 to 50 days after a single injection, suggesting that once-monthly or even less frequent dosing may be possible, according to a poster presentation at the XIX International AIDS Conference (AIDS 2012) recently held in Washington, DC.
AIDS 2012: Cobicistat Matches Ritonavir as Booster for Atazanavir
- Details
- Category: HIV Treatment
- Published on Monday, 30 July 2012 00:00
- Written by Liz Highleyman
The novel boosting agent 
cobicistat works as well as ritonavir (Norvir) as a pharmacoenhancer, or booster, for the first-line protease inhibitor atazanavir (Reyataz) at 48 weeks, according to a report presented last week at the 19th International AIDS Conference in Washington, DC.
AIDS 2012: Once-daily Elvitegravir Suppresses HIV as well as Raltegravir at 96 weeks
- Details
- Category: HIV Treatment
- Published on Monday, 30 July 2012 00:00
- Written by Liz Highleyman
The investigational HIV integrase inhibitor elvitegravir taken once-daily continued to perform as well as twice-daily raltegravir (Isentress) at 96 weeks for treatment-experienced people with extensive drug resistance, according to data presented last week at the 19th International AIDS Conference (AIDS 2012) in Washington, DC.
AIDS 2012: Dolutegravir Matches Raltegravir for People Starting HIV Treatment
- Details
- Category: HIV Treatment
- Published on Friday, 27 July 2012 00:00
- Written by Liz Highleyman
The novel integrase inhibitor dolutegravir worked as well as raltegravir (Isentress) at 48 weeks for treatment-naive people in the Phase 3 SPRING-2 study, according to a late-breaker presentation at the 19th International AIDS Conference (AIDS 2012) this week in Washington, DC.
Web Design and Development by